A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression

Molecular Therapy

Volumn 4, Issue 5, 2001, Pages 416-426

  Rubinchik, Semyon ^a   Wang, Danher ^b   Yu, Hong ^a   Fan, Fan ^a   Luo, Min ^a   Norris, James S ^a   Dong, Jian yun ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b GenPhar Inc   (United States)

Author keywords

Combined regulation; Expression amplification; Prostate specific promoter; Tetracycline expression system

Indexed keywords

CYTOTOXIC AGENT; DOXYCYCLINE; FAS LIGAND; GREEN FLUORESCENT PROTEIN; PROSTATE SPECIFIC ANTIGEN; TETRACYCLINE; TRANSACTIVATOR PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY; FUSION GENE; GENE CASSETTE; GENE EXPRESSION; GENE THERAPY; GENETIC CODE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PROSTATE CANCER; SAFETY; TUMOR CELL;

ADENOVIRIDAE; ANIMALIA; CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS;

EID: 0035191647     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0478     Document Type: Article

References (50)

1. Prodrug activation enzymes in cancer gene therapy
2. Gene therapy for cancer: From the laboratory to the patient
3. Prostate cancer gene therapy: Outcome of basic research and clinical trials
4. Adenoviruses as gene delivery vectors
5. Production of viral vectors for gene therapy applications
6. Replication-selective adenoviruses as oncolytic agents
7. Towards the use of replicative adenoviral vectors for cancer gene therapy
8. Mutant adenoviruses selectively replication-competent in tumor cells
9. β-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses
10. Potentials and limitations of adenovirus-p53 gene therapy for brain tumors
11. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer
12. Transduction of normal and malignant oral epithelium by an adenovirus vector: The effect of dose and treatment time on transduction efficiency and tissue penetration
13. Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: Effects of dibutyryl adenosine 3′,5′-cyclic monophosphate, α-glycyrrhetinic arabinoside
14. Ganciclovir-mediated cell killing and bystander effect is enhanced in cells with two copies of the herpes simplex virus thymidine kinase gene
15. Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells
16. Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer
17. Cell type specific and inducible promoters for vectors in gene therapy as an approach for cell targeting
18. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters
19. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells
20. Treatment of experimental glioma by administration of adenoviral vectors expressing Fas ligand
21. A family of ligands for the TNF receptor superfamily
22. Structure and function of Fas/Fas ligand
23. Cell-mediated cytotoxic mechanisms
24. Activation-induced death of mature T cells in the regulation of immune responses
25. Resistance to Fas (APO-1/CD95)-mediated apoptosis and expression of Fas ligand in esophageal cancer: The Fas counterattack
26. Fas-mediated apoptosis in tumor formation and defense
27. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles
28. Ionizing radiation alters Fas antigen ligand at the cell surface and on exfoliated plasma membrane-derived vesicles: Implications for apoptosis and intercellular signaling
29. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles
30. Downregulation of Fas ligand by shedding
31. Fas and Fas ligand interactions in malignant disease
32. Adenoviral vector which delivers FASL-GFP fusion protein regulated by the tet-inducible expression system
33. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis
34. Fas ligand is constitutively secreted by prostate cancer cells in vitro
35. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis
36. Creation of a new transgene cloning site near the right ITR of Ad5 results in reduced enhancer interference with tissue-specific and regulatable promoters
37. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo
38. Co-regulation of two gene activities by tetracycline via a bidirectional promoter
39. Human DU145 prostate cancer cells overexpressing mitogen-activated protein kinase phosphatase-1 are resistant to Fas ligand-induced mitochondrial perturbations and cellular apoptosis
40. Dominant nature of the resistance to Fas- and tumor necrosis factor-α-mediated apoptosis in human prostatic carcinoma cell lines
41. Modulation of growth and apoptosis response in PC-3 and LNCAP prostate-cancer cell lines by Fas
42. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis
43. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations
44. In vivo expression of soluble Fas and FAP-1: Possible mechanisms of Fas resistance in human hepatoblastomas
45. Transcriptionally regulated adenoviruses for prostate-specific gene therapy
46. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: Construction and testing of a tissue-specific adenovirus vector
47. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors
48. A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells
49. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene
50. Selective activation of the probasin androgen-responsive region by steroid hormones